None listed
Conditions
Interventions
Biological/Vaccine, Stem Cell : Product Name: CS20BR08
Drug Classification: Clinical Trials
Usage: dose: 0.1mL per 1 kg of patient weight
Route of administration: intrathecal injection
Appearance:
Sponsors
Corestem
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A person who has been diagnosed with any of the following conditions - Patients diagnosed as possible or probable multiple system atrophy, cerebellar subtype according to The Gilman Criteria (2008) - Patients diagnosed with Sporadic adult onset cerebellar ataxia who have not been identified as other causes according to Abele et al. criteria -Patients diagnosed with spinocerebellar ataxia on clinical and genetic tests 2. Patients between 30 and 80 years old 3. Scale for the assessment and rating of ataxia (SARA) : below 20 points 4. Those who have no hematological abnormalities 5. Those who have written their consent for research
Exclusion criteria
Exclusion criteria: 1. Participitants who are suspected dementia on the K-MMSE test 2. In the case of vascular brain lesion coexisting on radiographic images 3. When severe medical illness coexists 4. Participitants who have a condition that affects your long-term survival 5. pregnant women, lactating women. 6. Under participating in other clinical trials or other stem cell therapy within 6 months 7. HLA antibody is found before administration of test drug 8. Patients deemed inappropriate for participation in clinical trials by other investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scale for the assessment and rating of ataxia (SARA) | — |
Secondary
| Measure | Time frame |
|---|---|
| gait analysis (Gait-rite) | — |
Countries
Korea, Republic of
Contacts
Public ContactPANWOO KO
Kyungpook National University Medical Center
Outcome results
None listed